US FDA Approves Acadia Pharmaceuticals’ DAYBUE to Treat Rett Syndrome
Acadia Pharmaceuticals, Inc. (ACAD) announced that DAYBUE (trofinetide), a treatment for Rett syndrome, has been approved by the US FDA for use in adults and children over the age of two. The first and only drug that has been approved for the treatment of Rett syndrome is DAYBUE. This day marks a significant turning point […]
Continue Reading